Price T Rowe Associates Inc. MD boosted its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) by 48.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,110,462 shares of the company’s stock after purchasing an additional 1,333,892 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.06% of SpringWorks Therapeutics worth $202,318,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SWTX. Russell Investments Group Ltd. raised its position in shares of SpringWorks Therapeutics by 49.0% in the first quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock valued at $8,370,000 after buying an additional 55,893 shares during the last quarter. Seven Eight Capital LP acquired a new position in SpringWorks Therapeutics in the 4th quarter valued at $1,544,000. Perceptive Advisors LLC lifted its stake in shares of SpringWorks Therapeutics by 28.7% during the 4th quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock worth $71,439,000 after purchasing an additional 436,830 shares during the period. Point72 Asset Management L.P. boosted its holdings in shares of SpringWorks Therapeutics by 310.7% during the fourth quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock worth $78,919,000 after purchasing an additional 1,635,722 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of SpringWorks Therapeutics during the fourth quarter worth $12,331,000.
SpringWorks Therapeutics Trading Up 3.2 %
Shares of SWTX traded up $1.17 during trading hours on Friday, hitting $38.04. The stock had a trading volume of 515,590 shares, compared to its average volume of 756,807. The company’s fifty day simple moving average is $39.06 and its 200 day simple moving average is $43.55. SpringWorks Therapeutics, Inc. has a 12-month low of $18.00 and a 12-month high of $53.92.
Wall Street Analyst Weigh In
Several equities analysts recently commented on SWTX shares. HC Wainwright reiterated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, May 31st. Wedbush reaffirmed an “outperform” rating and set a $75.00 price objective (up previously from $70.00) on shares of SpringWorks Therapeutics in a research note on Thursday, May 2nd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $68.83.
Get Our Latest Analysis on SWTX
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
Recommended Stories
- Five stocks we like better than SpringWorks Therapeutics
- What Are Growth Stocks and Investing in Them
- Is Crypto Cool Again? What Stocks You Should Be Watching
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Why Call Options Volume for These 2 Stocks Spiked Together
- Russell 2000 Index, How Investors Use it For Profitable Trading
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding SWTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report).
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.